This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. l-Type amino acid transporter 1 (LAT1) disulfide linked to CD98 heavy chain (hc) is highly expressed in most cancer cells, but weakly expressed in normal cells. In the present study, we developed novel anti-LAT1 mAbs and showed internalization activity, inhibitory effects of amino acid uptake and cell growth and antibody-dependent cellular cytotoxicity, as well as in vivo antitumor effects in athymic mice. Furthermore, we examined the reactivity of mAbs with LAT1 of Macaca fascicularis to evaluate possible side-effects of antihuman LAT1 mAbs in clinical trials. Antihuman LAT1 mAbs reacted with ACHN human and MK.P3 macaca kidney-derived cells, and this reactivity was significantly decreased by siRNAs against LAT1. Macaca LAT1 cDNA was cloned from MK.P3, and only two amino acid differences between human and macaca LAT1 were seen. RH7777 rat hepatoma and HEK293 human embryonic kidney cells expressing macaca LAT1 were established as stable transfectants, and antihuman LAT1 mAbs were equivalently reactive against transfectants expressing human or macaca LAT1. Dual (high and low) avidity modes were detected in transfectants expressing macaca LAT1, MK.P3, ACHN and HCT116 human colon cancer cells, and K A values were increased by anti-CD98hc mAb, suggesting anti-LAT1 mAbs detect an epitope on LAT1-CD98hc complexes on the cell surface. Based on these results, LAT1 may be a promising anticancer target and Macaca fascicularis can be used in preclinical studies with antihuman LAT1 mAbs.
| INTRODUC TI ON
CD98 was originally reported as a cell surface marker associated with lymphocyte activation, as defined by a 4F2 mAb, 1 and subsequently identified as a unique molecule expressed by numerous cancer cells. [2] [3] [4] CD98 with a molecular weight (MW) of 120~140 kDa (gp125 2, 3 ) is composed of a glycosylated heavy chain (hc) with a MW of 80~100 kDa and non-glycosylated light chains (lc) with a MW of 35~55 kDa. [1] [2] [3] [4] CD98hc, also referred to solute carrier (SLC)
3A2, binds to six CD98lc of the SLC7A amino acid transporter family (SLC7A5; LAT1, 7A8; LAT2, 7A7; y+LAT1, 7A6; y+LAT2, 7A10; asc1 and 7A11; xCT). [5] [6] [7] [8] [9] [10] [11] SLC7A11 (xCT) was identified as a molecule required for the maintenance of cancer stem cells (CSC). 12 In particular, a variant form of CD44 (CD44v) [12] [13] [14] [15] [16] [17] or human epidermal growth factor receptor 1 (HER1) 18 associates with xCT in epithelial cancers or gliomas, respectively, and stabilizes xCT, resulting in the survival of CSC in unfavorable conditions for cancers such as oxidative stress due to anticancer drugs. In this context, we demonstrated the antitumor effects of a fully human anti-CD44 mAb 19 recognizing CD44v bound to xCT expressed by CSC.
l-Type amino acid transporter 1 (LAT1) 5, 6 is the first identified CD98lc, and cancers from several tissues express both CD98hc 2,3,20-25 and LAT1 [25] [26] [27] [28] [29] proteins. The oncogenicity of CD98
was confirmed with wild-type CD98hc [30] [31] [32] [33] bound to CD98lc, but not with mutated CD98hc 32 lacking the cysteine residue needed for the association with CD98lc.
These results suggest that molecular complexes between CD98hc and some CD98lc are oncogenic, and we recently identified CD98hc-LAT1 as an oncogenic complex by targeted disruption of the chicken LAT1 gene. 34 CD98-LAT1 is therefore considered to be a promising target for cancer therapy. Although the major targets of existing anticancer therapeutic antibodies are receptor-type tyrosine kinases, overexpression of anti-HER1 and anti-HER2 is limited to cancers from squamous 35, 36 or glandular 37, 38 epithelium, respectively. As CD98/LAT1 is expressed by almost all cancers irrespective of tissue origin, 2, 3, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] anti-CD98/LAT1 therapeutic antibodies may be ideal against numerous human malignancies.
Although clinical trials with anti-CD98hc therapeutic antibodies (KHK2898 and IGN523) were recently started, 39 the cancer specificity of LAT1 is superior to that of CD98hc. 40, 41 However, LAT1 is a 12-pass membrane protein and has scarce extracellular domains, thus it was difficult to produce anti-LAT1 mAb reactive to living cancer cells. We previously reported the production of the first (1st) anti-LAT1 mAbs 40, 41 and antitumor effects of the anti-LAT1 mAb using a hybridoma therapy model system. 34 We have recently prepared second (2nd)-generation mAbs and reported anti-LAT1-based ImmunoPET detection of xenografted human cancers. 42 In this study, we compared the reactivity between 1st-and 2nd-generation anti-LAT1 mAbs against cancer cells and analyzed the internalization activity and inhibitory effects of amino acid uptake and cell growth by 2nd-generation mAbs. We then investigated the in vivo antitumor effects and antibody-dependent cellular cytotoxicity (ADCC) of rat mAbs with splenocytes from athymic mice and of rat-human chimeric anti-LAT1 mAbs with human mononuclear cells from peripheral blood (hMNC-PB) as ef- 
| Molecular cloning of macaca LAT1 cDNA
Macaca LAT1 cDNA was reverse-transcribed with First Strand cDNA Synthesis kit (GE Healthcare, Uppsala, Sweden) from total RNA of MK.P3 cells prepared by Isogen II (Nippon Gene, Toyama, Japan), and cDNA was amplified by Q5 DNA polymerase (New England BioLabs, Tokyo, Japan) using a primer set for the amplification of full-length macaca LAT1 mAbs.
| Establishment of transfectant cells expressing macaca LAT1-GFP
GFP was fused to full-length macaca LAT1 in a pAcGFP vector (BD Biosciences, Mountain View, CA, USA). Transfection of macaca LAT1-GFP vector into RH7777 or HEK293 cells was carried out using Lipofectamine 3000 (Invitrogen). Cells were selected with 400 μg/ mL G418 (Nacalai Tesque, Kyoto, Japan), and clone-sorted for cellular green fluorescence using a JSAN cell sorter (Bay Bioscience, Kobe, Japan).
| Primary mAbs and polyclonal antibodies
First-generation (SOL22 and SOL69), 34, 40, 41 46, 47 ) , and anti-GFP rabbit polyclonal antibodies (pAb) (produced in our laboratory) were used. 
| Animals

| Flow cytometry (FCM)
Cells
| Production of novel antihuman LAT1 rat mAbs and chimeric rat-human mAbs
| Internalization activity of anti-LAT1 mAbs
| In vivo antitumor effects of mAbs in athymic mice
KSN mice at 6 weeks of age were randomly separated into two groups (RM1 isotype-control rat IgG 2a or Ab1 anti-LAT1 rat IgG 2a ).
LS-174T human colon cancer cells (5 × 10 6 in 200 μL PBS) were s.c.
inoculated to mice, and visible tumors were confirmed in all mice.
At this point (day 0), anti-LAT1 mAb (Ab1) or isotype-control mAb (100 μg in 500 μL PBS) was i.p. injected, followed by two additional injections of the same amount of mAb on day 8 and day 15. Size of each tumor was periodically measured and tumor volume (mm 3 ) was calculated by the formula 0.4 × (length) × (width) 2 . ) were homogenized in 100 μL of assay buffer and subjected to an enzyme reaction in which BCAA were oxidatively deaminated, producing NADH which reduces the probe, generating a color product (λ max = 450 nm). Absorbance at 450 nm was measured using a Model 550 microplate reader (Bio-Rad, Hercules, CA, USA), and concentrations of cellular BCAA were calculated from the standard curve for leucine.
| Effects of the anti-LAT1 mAb on the uptake of branched chain amino acids
| In vitro inhibitory effects on cell growth of cancer cells by anti-LAT1 mAbs
HeLa, KATOIII or NCI-H1944 cells (1 × 10 3 cells in each well of a 96-well plate) were suspended in 100 μL serum-free RD medium without the mAb or with isotype-control rat IgG 2a (RM1), antihuman
CD98hc rat mAb (HR35), antihuman xCT rat IgG 2a (Ab31), or anti-LAT1 mAb (SOL69, Ab1 or Ab3) (0.02~20 μg/mL), and incubated for 4-7 days at 37°C. WST-8-based CCK-8 (Dojin Chemicals, Kumamoto, Japan) was added (5 μL/well), and absorbance at 450 nm was measured using a Model 550 microplate reader (Bio-Rad).
| Antibody-dependent cellular cytotoxicity
Antibody-dependent cellular cytotoxicity was measured by the 
| Immunoprecipitation analysis
Subconfluent cells in 10-cm dishes (Corning) were washed with PBS and lysed on ice for 30 minutes in 3 mL lysis buffer containing 1% Nonidet P-40 and protease inhibitor cocktail (Nacalai Tesque).
Resulting extracts were centrifuged at 19 000 x g for 10 minutes
at 4°C, and the supernatants were precleared with protein G Sepharose for 1 hour. Lysates were subjected to immunoprecipitation with antirat CD98hc (B3) or antihuman CD98hc (HBJ127) mouse mAb for 6 hours at room temperature, followed by the addition of protein G Sepharose and further incubation for 2 hours.
Bead-bound proteins were washed three times with 1% (v/v) Nonidet P-40 in PBS, suspended in 1× SDS-PAGE loading buffer, and boiled for 5 minutes, and the beads were then isolated by centrifugation. For immunoblotting analysis, proteins were solubilized in loading buffer, subjected to SDS-PAGE (8% gels) and transferred to Immobilon-P (Millipore), and exposed to rabbit anti-GFP pAb.
Immune complexes were detected by HRP-conjugated VeriBlot (ab131366; Abcam, Cambridge, UK) and Chemi-Lumi One Super (Nacalai Tesque).
| Scatchard plot analysis
Avidity 
| Statistical analysis
Experimental data were analyzed with Prism 7 for Windows (GraphPad Software, San Diego, CA, USA). Criteria for significance were P < .05 (*), .01 (**) and .001 (***).
| RE SULTS
| Novel (2nd-generation) antihuman LAT1 mAb
We previously reported the production of anti-LAT1 mAbs, 40, 41 designated as SOL22 and SOL69 (1st-generation mAbs). To advance LAT1-targeted cancer therapy, novel mAbs (Ab1~4; 2nd-generation mAbs) were developed against transfectants expressing human LAT1-GFP, and basic analyses on anti-LAT1 (Ab2)-based ImmunoPET 42 were reported. All six anti-LAT1 mAbs are of the rat IgG 2a heavy chain subclass with κ-type light chains. Details of mAb production were described in our previous reports. 40, 41 Although the amino acid sequence in the complementarity-determining region (CDR) between 1st-and 2nd-generation mAbs differs, amino acid sequences within each generation were almost identical with very few amino acid differences in the CDR. Details for the novel mAbs were described in the patent (no. 9,725,519, USA and no. 6,421,371, Japan).
| Comparison of 1st-and 2nd-generation anti-LAT1 mAbs
Anti-LAT1 mAbs (SOL22, SOL69, Ab1 and Ab2) bound to HEK293
and RH7777 cells expressing human LAT1-GFP in a GFP expression level-dependent way, indicating that four anti-LAT1 mAbs are specific for human LAT1 (Figure 1 ). Ab1 and Ab2 showed stronger reactions than SOL22 and SOL69 against HCT116 and LS-174T
human colon cancers (Figure 1) , indicating that the 2nd-generation mAbs have superior anticancer reactivity compared with the 1st-generation mAbs.
| Internalization activity of mAbs
HEK293 expressing LAT1-GFP were cultured with mAbs, and the internalization of LAT1-GFP was analyzed (Figure 2A ). Cell surface LAT1 proteins were reduced by all four anti-LAT1 mAbs, and intracellular LAT1-GFP proteins were observed (white arrows).
Internalization of LAT1 proteins was also seen in HCT116 colon ( Figure 2B ) and NCI-H1944 lung ( Figure 2C ) cancers with antihuman LAT1 mAbs. Internalization of LAT1 proteins was observed at 15 minutes, and cell surface LAT1 proteins decreased time-dependently until 120 minutes after the addition of mAbs ( Figure 2C ).
F I G U R E 1 Specificity and reactivity of anti-l-type amino acid transporter 1 (anti-LAT1) mAbs. Anti-LAT1 rat mAb (SOL22, SOL69, Ab1 and Ab2) were compared for their binding activity against HEK293 and RH7777 expressing human LAT1-GFP (A), and against human HCT116 and LS-174T human colon cancer cells (B). Cells were stained with primary anti-LAT1 rat mAbs, followed by secondary phycoerythrin-conjugated antirat IgG, and analyzed by flow cytometry (FCM). Values in (B) indicate the ratio (+ mAb/− mAb) of mean fluorescence intensity (rMFI)
| Antitumor effects of mAb on the growth of xenografted human cancer cells
Ab1 was evaluated for its antitumor effects against LS-174T human colon cancer cells in an established tumor model. 19, 48 In this systemic administration of the mAb to tumor-bearing mice, we deliberately adopted i.p. injection to give an exact amount of mAb to each mouse.
Tumor growth in Ab1-treated mice was significantly inhibited (Figure 3 ).
| In vitro effects of anti-LAT1 mAb on BCAA uptake and growth of human cancer cells
To analyze the mechanisms of the in vivo antitumor effects by anti- 
| Antibody-dependent cellular cytotoxicity by rat mAbs and human-rat chimeric mAbs
Anti-LAT1 rat mAb-mediated ADCC activity was examined as part of the analysis of the in vivo antitumor effects ( Figure 4E ). In LS174T
and HeLa human cancer cells, Ab1 showed significant ADCC activity with splenocytes from athymic mice. Next, Ab1 and Ab3 rat mAbs were reshaped to ChAb1 and ChAb3 rat-human chimeric mAbs and evaluated for ADCC activity against hMNC-PB (human lymphocytes). Chimeric anti-LAT1 mAbs showed strong ADCC activity against many human cancer cells from the colon, uterus, lung, and ovary ( Figure 5A ). Furthermore, the ADCC activity of anti-LAT1 chimeric mAbs was markedly superior to chimeric anti-HER1 (Cetuximab) against HCT116 ( Figure 5B ).
| Cross-reactivity of antihuman LAT1 mAbs with macaca LAT1 proteins
Evaluation of side-effects of therapeutic mAbs is important for clinical use. However, mAbs against a given human protein ) were s.c. inoculated into athymic mice, visible tumors were confirmed in all mice. At this point (day 0), anti-LAT1 mAb (Ab1) or isotype control IgG mAb (100 μg) was i.p. injected, followed by two additional injections of the same amount of mAb on day 8 and day 15. Data were expressed as mean ± SEM, and statistical analysis was done using two-way analysis of variance (temporarily X) often do not react with X of other species. Indeed, antihuman LAT1 mAbs are specifically reactive with LAT1, but not with other human CD98lc, 40, 41 or mouse LAT1. 42 Therefore, we investigated the reactivity of Ab1 and Ab2 with LAT1 of M. fascicularis, which is generally used as non-human primate for the preclinical evaluation of side-effects. Ab1 and Ab2 were confirmed to be reactive against MK.P3 macaca kidney-derived cells, and this reactivity was equivalent to that against ACHN human cells ( Figure 6A ).
| Novel mAbs specifically recognize human and macaca LAT1 proteins
To confirm that the reactivity of antihuman LAT1 mAbs with macaca cells was specific for macaca LAT1, we analyzed the ef- 
| Reactivity of mAbs with transfectants expressing macaca LAT1-GFP
To substantiate the equivalent reactivity of antihuman LAT1 mAb against human and macaca LAT1, we established RH7777 cells expressing GFP-fused human or macaca LAT1. Ab1, the antihuman LAT1 mAb, bound to both RH7777 transfectants in a GFP expression level-dependent way, and the rMFI reflecting the relative amount of cell-bound anti-LAT1 mAb was almost equal in both RH7777 transfectants ( Figure 6C ).
| Introduced macaca LAT1 associates with endogenous CD98hc
The possible association of macaca LAT1-GFP proteins with endogenous In (B), growth-inhibitory effects of anti-LAT1 (SOL69 and Ab1), anti-CD98hc (HR35) or anti-xCT (Ab31) mAb (20 μg/mL) were also evaluated with isotype control rat mAb (RM1). E, Antibody-dependent cellular cytotoxicity activity of anti-LAT1 rat mAb (Ab1) with splenocytes from athymic mice was evaluated in LS-174T and HeLa cells. Effector to target (E/T) ratio was 5:1. Vertical bars show standard errors, and data were analyzed statistically by two-sided Student's t tests. LDH, lactate dehydrogenase; ns, not significant. *P < .05, **P < .01 and ***P < .001.
F I G U R E 5 Antibody-dependent cellular cytotoxicity (ADCC) of chimeric anti-l-type amino acid transporter 1 (anti-LAT1) mAbs with human effector cells. A, ADCC activity of rat-human chimeric anti-LAT1 mAbs (ChAb1 and ChAb3) with human lymphocytes was evaluated against different human cancer cell lines. B, ADCC of anti-LAT1 chimeric mAbs was compared with that of Cetuximab, an antihuman epidermal growth factor receptor 1 chimeric mAb. E/T ratio was 50:1. Vertical bars show standard errors, and data were analyzed statistically by two-sided Student's t tests. LDH, lactate dehydrogenase F I G U R E 6 Specificity of antihuman l-type amino acid transporter 1 (LAT1) mAbs in human and macaca cells. A, ACHN human and MK. P3 macaca cells were stained with antihuman LAT1 mAbs (Ab1 or Ab2), followed by phycoerythrin (PE)-conjugated antirat IgG, and analyzed by flow cytometry (FCM). Values indicate the ratio (+ mAb/− mAb) of mean fluorescence intensity (rMFI). B, Effects of RNA interference on the expression of human LAT1 and CD98 heavy chain (CD98hc) proteins in human and macaca cells were analyzed. Cells were treated with mock (scramble) or LAT1 siRNA (#1, #2 or #3) for 72 h, stained with rat mAbs against human LAT1 (Ab1) or CD98hc (HR35), followed by PEconjugated antirat IgG, and analyzed for protein expression by FCM. C, Antihuman LAT1 mAb (Ab1) was evaluated for its reactivity against RH7777 rat cells expressing macaca (left) or human (right) LAT1-GFP. D, Association of introduced macaca LAT1-GFP with endogenous rat or human CD98hc was examined. Cell lysates from RH7777 (upper) or HEK293 (lower) expressing macaca LAT1 were subjected to immunoprecipitation with control IgG, anti-LAT1, or anti-CD98hc mAb, and the resulting precipitates, as well as the original cell lysates (input), were subjected to immunoblotting with anti-GFP rabbit polyclonal antibodies or anti-CD98hc mAb followed by western blotting with anti-GFP pAb.
Exogenously expressed macaca LAT1 bound to rat CD98hc in RH7777 rat cells and to human CD98hc in HEK293 human cells ( Figure 6D ). 
| Dual avidity modes of antihuman LAT1 mAbs
| D ISCUSS I ON
The CD98hc-LAT1 complex is regarded as a promising molecular target for cancer therapy, and antibody therapy against CD98hc is 39 We previously showed that the cancer specificity of LAT1 is superior to that of CD98hc 40, 41 by analyses with 1st-generation anti-LAT1 mAbs, and we recently developed 2nd-generation anti-LAT1 mAbs.
42
The 2nd-generation anti-LAT1 mAbs had markedly stronger reactivity against HEK293 and RH7777 cells expressing human LAT1-GFP, HCT116 and LS-174T human colon cancer cells than the 1st-generation mAbs (Figure 1 ).
In the present study, we examined in vitro mAb-dependent inter- In the present study, we found high and low avidity modes between antihuman LAT1 mAb and human or macaca cells (Figures 7   and 8 ). We purposely used the term "avidity" rather than "affinity"
because the experiments were carried out with divalent mAbs bound sis, using an anti-LYVE-1 mAb. 53 At present, many transporters are not considered to be target molecules for cancer therapy; however, this study strongly suggests that inhibition of cancer metabolism by mAbs against amino acid transporters will play a significant role in future cancer therapies.
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